Presentation of CXCL12γ by heparan sulfate proteoglycans activates CXCR4 without desensitization in normal and malignant B cells.

Saved in:
Bibliographic Details
Title: Presentation of CXCL12γ by heparan sulfate proteoglycans activates CXCR4 without desensitization in normal and malignant B cells.
Authors: Lantermans HC; Department of Pathology, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands., Ma F; Department of Pathology, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands., Kuil A; Department of Pathology, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands., de Rooij MFM; Department of Pathology, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands., Bergkamp ND; Amsterdam Institute for Molecular and Life Sciences, Division of Medicinal Chemistry, Department of Chemistry and Pharmaceutical Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., van der Meer W; Department of Medical Biochemistry, Vascular Cell Biology Laboratory, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Section Molecular Cytology at Swammerdam Institute for Life Sciences, Leeuwenhoek Centre for Advanced Microscopy, University of Amsterdam, Amsterdam, The Netherlands., van Buul JD; Department of Medical Biochemistry, Vascular Cell Biology Laboratory, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Section Molecular Cytology at Swammerdam Institute for Life Sciences, Leeuwenhoek Centre for Advanced Microscopy, University of Amsterdam, Amsterdam, The Netherlands., Smit MJ; Amsterdam Institute for Molecular and Life Sciences, Division of Medicinal Chemistry, Department of Chemistry and Pharmaceutical Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Kersten MJ; Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.; Department of Hematology, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands., Spaargaren M; Department of Pathology, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands., Pals ST; Department of Pathology, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands.
Source: Blood advances [Blood Adv] 2025 May 13; Vol. 9 (9), pp. 2307-2320.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2024014396